

Special Issue

Nanomedicine with Neuroprotective Activity

Message from the Guest Editors

Neurodegenerative disease is a type of neurological disorder that alters brain functionality due to the progressive deterioration of neurons in different brain regions. The most common neurodegenerative diseases are AD and PD. Aging populations are the main target for these diseases as older people experience cognitive impairments, decrease in muscle control and motor coordination, impaired language, memory loss, and a reduction in quality of life. As stated by the World Health Organization, neurodegenerative disease will be the biggest health issue of the twenty-first century. However, there is no specific treatment to cure these diseases; rather, it is the symptoms which are treated. Conventional drug delivery methods cannot cross these barriers at a lower dosage, whereas a higher dosage can cause severe adverse neurotoxicity. Nanoparticle-based drug delivery systems not only amplify drugs' therapeutic effects but also mitigate toxicity that can be caused due to overdosage. This Special Issue intends to publish papers which focus on the recent advances in nanotechnology or nanoparticle-based drug delivery systems involved in treating neurodegenerative diseases.

Guest Editors

Dr. Venkatesan Perumal

Dr. Arun Reddy Ravula

Dr. Agnieszka Agas

Deadline for manuscript submissions

closed (25 February 2025)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/187459

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)